The pathophysiology of major depressive disorder (MDD) is not fully understood and the diagnosis is largely based on history and clinical examination. So far, several lines of preclinical data and a single imaging study implicate a role for the serotonin 1B (5-HT 1B ) receptor subtype. We sought to study 5-HT 1B receptor binding in brain regions of reported relevance in patients with MDD. Subjects were examined at the Karolinska Institutet PET centre using positron emission tomography (PET) and the 5-HT 1B receptor selective radioligand [ binding potential was significantly lower in the MDD group compared with the healthy control group in the anterior cingulate cortex (20% between-group difference), the subgenual prefrontal cortex (17% between-group difference), and in the hippocampus (32% between-group difference). The low anterior cingulate [
Introduction
There is a wealth of studies underlining the importance of the serotonin system in the pathophysiology and treatment of major depressive disorder (MDD) (Jans et al., 2007; Lundberg et al., 2012; Ressler and Nemeroff, 2000) . Out of the 14 different serotonin receptor subtypes (Barnes and Sharp, 1999) , the 5-hydroxytryptamine(5-HT) 1A and 5-HT 1B receptor are the inhibitory receptors best characterized and known to modulate neural transmission via G i -protein-mediated inhibition of adenylate cyclase (Barnes and Sharp, 1999; Hoyer et al., 2002) . Due to the availability of selective radioligands the 5-HT 1A receptor is by far the most studied with regard to its relationship to MDD. Some (Drevets et al., 2007; Savitz and Drevets, 2013) but not all (Shrestha et al., 2012 ) molecular imaging studies have reported lower 5-HT 1A receptor binding in the brain in depressed subjects when compared with controls.
Whereas the 5-HT 1A receptor is a somatodendritic receptor, the 5-HT 1B receptor is located to the membrane of preterminal axons where it functions as a presynaptic autoreceptor on serotonergic neurons or as a postsynaptic heteroreceptor when located on GABA or glutamatergic neurons (Riad et al., 2000; Ruf and Bhagwagar, 2009 ). 5-HT 1B autoreceptors inhibit the release of serotonin from the presynaptic bulb (Briley and Moret, 1993) . The 5-HT 1B receptors in brain are widely distributed to serotonergic projection areas, with highest densities found in substantia nigra and globus pallidus and intermediate binding in neocortex and striatum (Varnas et al., 2001) . Accumulating evidences imply that the 5-HT 1B receptor may be involved in the pathophysiology of MDD. In animal studies low 5-HT 1B receptor mRNA in the dorsal raphe nucleus in rats has been reported to predispose learned helplessness (Neumaier et al., 2002) , and 5-HT 1B receptor binding is low in the hippocampus of sensitive, maternally-separated rats (Shrestha et al., 2013) . In humans, Huang et al. have reported an association between the 5-HT 1B receptor gene polymorphism G861C and MDD (Huang et al., 2003) . Also, lower 5-HT 1B mRNA expression in the frontal cortex and higher in the paraventricular nucleus of hypothalamus has been demonstrated in suicide victims compared with controls (Anisman et al., 2008) . Finally, in a recent PET-study using the (Gallezot et al., 2010; Pierson et al., 2008; Zimmer and Le Bars, 2013 (Gallezot et al., 2010; Paterson et al., 2013; Varnas et al., 2011) . [ 11 C]AZ10419369 has recently proven suitable for detailed mapping of 5-HT 1B receptors in the human brain Varnas et al., 2011) . The reproducibility of [ 11 C]AZ10419369 binding has been examined in humans, with 5-7% test-retest variability in cortical regions and 7-14% in subcortical regions (Nord et al., 2014) . In studies of the neuroanatomy of depression, two brain regions have been more consistently related to MDD than others, the anterior cingulate cortex and hippocampus. Low blood flow and metabolism in the anterior cingulate cortex is a replicated finding in MDD (Drevets et al., 2002 (Drevets et al., , 1997 Pizzagalli et al., 2004) . Reduced volume of the subgenual part of the anterior cingulate cortex has been demonstrated in a meta-analysis of volumetric studies (Hajek et al., 2008) . Likewise, low volume has also been reported for the hippocampus (Kempton et al., 2011) , the part of the brain having the most extensive serotonergic innervations (Berumen et al., 2012) .
The aim of the present study was to use PET and [ 11 C]AZ10419369 to compare 5-HT 1B receptor binding in patients with recurrent MDD with age and sex-matched controls. The hypothesis was that 5-HT 1B receptor binding would be aberrant in the anterior cingulate cortex, ventral striatum and pallidum in the depressed subjects.
Methods

Subjects
The study was approved by the Regional Ethical Review Board in Stockholm and by the Radiation safety committee of the Karolinska University Hospital. The patients were originally examined in a study of the mechanism of action of cognitive behavioral therapy for MDD . All but one patient were recruited through advertisement in a morning paper as previously described . Eleven out of 116 volunteers met the criteria for participation in the study, and were included after giving written informed consent. Inclusion criterion was an ongoing untreated moderate major depressive episode within major depressive disorder (MDD). The exclusion criteria were: bipolar disorder, organic brain disorder, drug or alcohol abuse, MADRS (Montgomery Åsberg Depression Rating Scale (Montgomery and Asberg, 1979) ) score below 20 or higher than 35, suicidality (defined as 4 4 on item 10 in MADRS), age 480 or o20 years, ongoing psychopharmacological treatment (wash out-period 4 1 month) and pregnancy. The most common reason for exclusion was ongoing medication (n ¼70), followed by not having a major depressive episode of moderate severity within recurrent MDD (n ¼13), somatic disease (n¼ 9), claustrophobia (n ¼4), not eligible age (n ¼4), not giving informed consent (n ¼2), not eligible for MRI (n ¼1) and other reasons (n¼ 2).
Each patient was assessed by a psychiatrist, using the structured clinical interview M.I.N.I. (Sheehan et al., 1998) . All patients had an ongoing depressive episode of moderate severity (median duration 11.5 months), within recurrent MDD (Table 1 ). The median MADRS score was 25.5, range 20-35. Comorbidity was found in two patients, one patient suffering from social phobia and another patient having both social phobia and generalized anxiety disorder. Except for psychiatric history, the patients were essentially healthy, according to medical history, physical examination, blood analysis and magnetic resonance imaging of the brain. The ongoing episode had not been treated prior to inclusion in the study. For the patients with previous psychopharmacological treatment for MDD the medication free period was on average 5.2 years (range 1-10 years). The patients were unmedicated, except for one female patient who was treated with 50 mg daily of the selective β 1 -adrenoceptor antagonist metoprolol. Half of the patients had a family history of major depressive disorder. One patient withdrew from the study, after experiencing panic during the PET examination, which had to be interrupted. Ten patients fulfilled the study according to protocol.
Control subjects matched for gender and age (7 3 years) were recruited from either advertisements in a newspaper or from a web site for scientific volunteers. The data from four of the controls has originally been published as part of a case-control study of Parkinson's disease . The controls had no previous psychiatric history, and were mentally healthy based on a structured clinical interview performed by a psychiatrist (M.T.) using either M.I.N.I. (n ¼6) or the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) (n¼ 4). Except from further psychiatric assessment, the controls underwent the same examinations as the patients in the study.
Magnetic resonance imaging
For one of the patients and four of the controls MRI examinations were performed with 1.5T (GE Signa). Nine patients and six controls were examined with a 3T system (GE Signa). The reason for the different MRI equipment in the study was an upgrade of the MR system at the Karolinska Hospital MR centre. The MRI protocol included a T1-weighted 3-dimensional sequence for coregistration with PET images and a T2-weighted sequence to rule out pathology.
Positron emission tomography -experimental procedure
At the day of the PET examination the patients were assessed by a psychiatrist (M.T.) applying MADRS and the Clinical Global Impression scale-Severity (CGI-S (Guy, (1976) ), to estimate the severity of the depression at time of PET. As a validation, the patients completed the self rating version of MADRS (MADRS-S) (Svanborg and Asberg, 2001 ). Urine analysis for drug screening for metamphetamine, cocaine, cannabis, bensodiazepines, methadone, barbiturates, amphetamine, opiates, phencyclidine and buprenorphine was performed in all subjects before the PET measurement, to exclude the use of drugs at time of PET. In each PET measurement the subject was placed recumbent with the head in the gantry of the PET system. A head fixation system with an individual plaster helmet was used (Bergstrom et al., 1981) .
[ 11 C]AZ10419369 was synthesized from its desmethyl precursor as previously described . [ 11 C]AZ10419369 in a sterile physiological phosphate buffer (pH 7.4) solution was diluted with saline to the volume of 10 ml and then injected as a bolus within 10 s into a cannula inserted into an antecubital vein. The cannula was then immediately flushed with 10 ml saline. Each subject was examined with PET and the radioligand [ 11 C]AZ10419369. The PET system used was ECAT HRRT (High Resolution Research Tomograph, Siemens Molecular Imaging) with a spatial resolution of approximately 1.5 mm in the centre and 2.4 mm at 10 cm off-centre full-width at half maximum with the current protocol (Varrone et al., 2009) . List mode data were acquired for 93 min. Images were reconstructed in a series of 37 frames of increasing duration (8 Â 10 s, 5 Â 20 s, 4 Â 30 s, 4 Â 60 s, 4 Â 180 s, 12 Â 360 s) using the ordinary Poisson 3D ordered subset expectation maximization algorithm, with 10 iterations and 16 subsets, including modeling of the system resolution (Varrone et al., 2009 ).
Image analysis
For eight of the patients and nine of the controls the PET images were corrected for head motion with a frame-to-framerealignment algorithm as previously described (Schain et al., 2012) . The head movements of two of the patients and one of the controls exceeded the limits of this method and their PET images were hence reconstructed using frame specific attenuation-data, according to a procedure described earlier .
T1-weighted (T1-w) MRI-images were coregistered to PETimages and segmented into grey matter, white matter and cerebrospinal fluid using SPM5 (Statistical Parametric Mapping, Wellcome Trust Centre for Neuroimaging, U.K.). The PET data were corrected for partial volume effects (PVE) according to the method developed by Meltzer et al. (1990) . PVE correction was performed using an in-house script implemented in MATLAB, as previously described (Schain et al., 2012) . The analysis of PET data was based on regions of interest (ROIs). Eight ROIs were chosen based on relevance for the pathophysiology of MDD according to the literature and the previous case-control PET study of 5-HT 1B receptors in MDD (Drevets, 2000; Murrough et al., 2011; Savitz and Drevets, 2013) : orbitofrontal cortex, anterior cingulate cortex (ACC), subgenual prefrontal cortex(SGPFC), amygdala, hippocampus, ventral striatum, pallidum and dorsal brain stem (DBS), and for reference cerebellum. The ROIs were defined manually on the MR images as previously described (Varnas et al., 2011) , except DBS and SGPFC. The DBS ROI was defined to include especially the median raphe nuclei, by delineation of the dorsal half of the brainstem on 5 consecutive horizontal MR sections ranging from the lower limit of the inferior colliculi to the isthmus (Kranz et al., 2012; Tiger et al., 2014) . SGPFC was defined as described by Drevets et al., (Drevets et al., 1997) . The SGPFC ROI was thus located adjacent and ventral to the ACC ROI, without overlap between the two ROIs (Fig. 1) . Volumes of the ROIs delineated on MR images were acquired with SPM5, and the ROI volumes of the patients were compared with those of the controls. BP ND values were calculated with the simplified reference tissue model (SRTM) (Lammertsma and Hume, 1996) , implemented in Matlab R2007b for Windows. The cerebellum was chosen as reference region, due to its negligible 5-HT 1B receptor density (Varnas et al., 2001 ).
Statistical analysis
The regional BP ND -values obtained from the PET measurements and the volumes of the manually defined ROIs of the patients were compared with those of the matched controls using independent t-tests, with two-tailed p-values. BP ND statistics was not corrected for multiple comparisons. Correlations between [ 11 C]AZ10419369 BP ND and age and MADRS were examined using Pearson's correlation. Group*age interactions were tested for with two-way AN-OVA. The statistical analyses were conducted using IBM SPSS Statistics 22 for Windows (SPSS Inc, Somers, NY, USA).
Results
Demographic characteristics for the patients and controls are presented in Table 1 . Ten out of the 11 patients and 10 matched controls completed the study according to protocol. After intravenous injection of [ 11 C]AZ10419369, there was a rapid increase in brain radioactivity with higher radioactivity in brain regions known to contain the 5-HT 1B receptor ( (Fig. 2, Table 2 ). In the subgenual prefrontal cortex the BP ND was 17% lower for the patients than for the controls (p ¼0.026). The largest difference was found in the hippocampus, with 32% lower [ 11 C]AZ10419369 binding in the depressed patients (p ¼0.012). For other regions in the brain, including the ventral striatum and pallidum, there were no significant differences in BP ND between patients and controls. The average BP ND in the whole brain was lower for the patients than for the controls (0.81 versus 1.01, p ¼0.043).
The hippocampus region was larger in the patients than in the controls (3.92 ml versus 3.31 ml, p ¼0.001) ( Table 2 ). The BP ND in hippocampus remained low in the MDD patients, also when adjusting for differences in ROI volumes (0.33 versus 0.58, p ¼0.001). There were no significant volume differences for any of the other examined brain regions.
For 
Discussion
The main finding in this study was lower [ 11 C]AZ10419369
binding to the 5-HT 1B receptor in the anterior cingulate cortex in patients with MDD when compared with controls. The BP ND was also low in the hippocampus and in the subgenual prefrontal cortex in MDD patients, whereas there were no significant differences in the other examined brain regions. Several lines of research point to the importance of the anterior cingulate cortex in the pathophysiology of MDD. At physiological conditions, the rostral anterior cingulate cortex is involved in emotional regulation, related to motivation and assignment of emotional valence to stimuli (Bush et al., 2000; Devinsky et al., 1995) . In functional PET studies of healthy volunteers, it has been reported that cerebral blood flow in the subgenual anterior cingulate cortex is increased during sad mood (George et al., 1995; Mayberg et al., 1999) . In a meta-analysis of functional imaging studies of the neuroanatomy of emotion sadness was over twice as frequently reported as any other emotion during activation of the subgenual anterior cingulate cortex (Phan et al., 2002) . Pre-and subgenual parts of the anterior cingulate cortex regulate negative emotional responses (Etkin et al., 2011) . In clinical fMRI studies abnormal activity in the ACC in subjects with MDD has been a common finding (Steele et al., 2007) . In case-control studies using [ 18 F]FDG-PET, increased metabolism in the subgenual anterior cingulate cortex in MDD has been reported (Drevets et al., 2008b) . These findings have contributed to the rational for reversible lesioning of the subgenual anterior cingulate cortex with deep brain stimulation, a treatment which indeed has shown antidepressive effects (Mayberg et al., 2005) . Moreover, cingulotomy, inducing a lesion in the ACC, has since many years been used for treatment of patients with chronic refractory depression (Steele et al., 2008) . Thus, the present study adds to a line of evidences implicating a role for the anterior cingulate cortex in MDD.
The lower [ 11 C]AZ10419369 BP ND found in the ACC in depressed patients compared with controls might reflect either higher serotonin concentration or lower 5-HT 1B receptor density. Low 5-HT 1B receptor density in the ACC of patients with MDD would be in line with the low mRNA concentration of the functionally related protein p11 reported for the ACC in patients suffering from MDD (Svenningsson et al., 2006) . The multifunctional protein p11 has a proposed role in the pathophysiology of MDD and in response to antidepressants . Early reduction of p11 in natural killer cells and monocytes with SSRI treatment has been found to correlate with antidepressant response in patients with MDD . p11 knockout in mice has resulted in a depressive phenotype with reduced numbers of 5-HT 1B receptors at the cell membrane (Svenningsson et al., 2006) . The view that 5-HT 1B receptor expression in the cell membrane is dependent on p11 has received consistent support from studies using brain tissue from p11 KO mice as well as immunohistochemistry and in situ hybridization, and co-expression of 5-HT 1B receptors has been demonstrated in p11 containing cells in the cingulate cortex (Egeland et al., 2011; Svenningsson et al., 2013) . Finally, significant correlations between 5-HT 1B receptor and p11 mRNA have been found post-mortem in frontopolar cortex, orbitofrontal cortex and hippocampus in depressed as well as control subjects (Anisman et al., 2008) . Thus, low 5-HT 1B receptor density in the ACC in depressed patients would be consistent with the previous findings of low p11 mRNA in the ACC in MDD (Svenningsson et al., 2006) . Alternatively, the low [
11 C]AZ10419369 BP ND found in the ACC in MDD could reflect high serotonin concentration. Sensitivity to endogenous serotonin levels has been demonstrated for [ 11 C]AZ10419369 in non-human primates, after challenges with fenfluramine (Finnema et al., 2010) or supratherapeutic doses of the selective serotonin reuptake inhibitor escitalopram (Nord et al., 2013) , expected to yield a marked increase of extracellular serotonin in brain. The lower regional BP ND may thus be explained by a higher synaptic concentration of serotonin in MDD compared to control subjects. However, this interpretation does not find support in post mortem data. In two studies of serotonin concentration in brain of depressed suicide victims and controls there was no elevation of the serotonin concentration in cortical regions or hippocampus (Cheetham et al., 1989; Owen et al., 1986) . Although high synaptic serotonin concentration cannot be ruled out, we find it more likely that the low [ 11 C]AZ10419369 BP ND in the ACC of the examined depressed patients reflects low 5-HT 1B receptor density. Importantly, irrespective of whether the findings reflect high serotonin concentration or low 5-HT 1B receptor density, our results support the current hypothesis on a role for serotonergic neurotransmission in the anterior cingulate cortex in the pathophysiology of MDD (Drevets et al., 2008a; Mayberg, 1997) .
In our previous study we found no significant change in [ 11 C]AZ10419369 BP ND in the ACC with psychotherapy for depression . A possible interpretation of this finding is that the low BP ND in the ACC is a vulnerability trait for developing depression, rather than a result of the depressive state. All the examined patients in this study had recurrent depressive episodes. The reduced BP ND in the ACC could also be a consequence of the major depressive disorder itself, since it was found irrespective of family history for depression. (Drevets et al., 2007; Savitz and Drevets, 2013) . Albeit functionally similar, these two 5-HT 1 receptors are expressed on different hippocampal neurons, with 5-HT 1A receptors being postsynaptical heteroreceptors and 5-HT 1B receptors mainly presynaptical autoreceptors (Riad et al., 2000; Sari, 2004) , and in different cortical layers (Laurent et al., 2002; Meunier et al., 2013; Riad et al., 2000) . A more detailed understanding of serotonergic innervation of the hippocampus is required to build a unified model capturing these observations. In contrast with the previously published PET study on 5-HT 1B receptor binding in MDD (Murrough et al., 2011) we found no significant difference in BP ND in the ventral striatum or pallidum. In that study, Murrough and coworkers used a different radioligand, [
11 C]P943, and reported results from a single ROI, "ventral striatum/ventral pallidum", but no data were provided for the ROIs showing aberrations in the present study. The patient cohort in the study by Murrough et al. is similar to ours, with unmedicated patients with recurrent MDD, with a relatively long duration of the current episode (9.4 versus 11.5 months) and similar wash-out period (4 weeks versus 1 month). The patient sample in the [ 11 C]P943 study of MDD differs from ours in the following aspects:
higher proportion of drug-naïve patients (nine versus four out of ten), patients were over-weight, bordering on obese (average BMI 29.7 versus 23.4 in our patient sample) and smokers were included. It is not clear whether any of these differences could explain the 5-HT 1B receptor binding discrepancy found in the ventral striatum and pallidum in the two PET studies of 5-HT 1B receptors in the brain in MDD. The average whole brain [ 11 C]AZ10419369 BP ND was lower in the MDD patients than in the controls. It could be argued that there may have been a change in the serotonergic neurotransmission in the raphe nuclei in the MDD group, which has affected the brain globally. Indeed, there was higher BP ND in the DBS in the MDD patients, which could reflect higher BP ND in especially the median raphe nucleus, that theoretically would lower serotonin release in serotonergic projection areas (Schlicker et al., 1997) . This would harmonize with the distinct BP ND reduction in the DBS after psychotherapy for MDD that we have previously reported . However, the difference in DBS BP ND between MDD patients and controls was not significant. Further research with optimized delineation of the rostral raphe nuclei is needed to determine the effect of MDD on 5-HT 1B receptor binding in the raphe nuclei.
The sample size in the present molecular imaging study of unmedicated patients with recurrent major depressive disorder was small, although comparable with earlier PET studies (Murrough et al., 2011; Savitz and Drevets, 2013) . To avoid the risk of type II errors inherent with this limited statistical power and expected interindividual variation and to reduce chance findings by repeated testing, the controls were matched carefully with their patients and the analysis hypothesis driven.
The specific radioactivity was higher in the MDD patients compared with the controls. If the specific radioactivity would have been low, the injected mass needed to obtain the radioactivity dose would have been high. This could have led to a mass effect, with displacement of radioligand binding by unlabeled compound. However, given the low masses injected in this study, mass effects are unlikely. Furthermore, there was no significant difference in injected mass between MDD patients and controls.
A potential issue in this study is the use of two different MRI scanners, with 1.5 or 3 T magnetic flux density respectively. To minimize the consequence of this difference we defined the ROIs manually. Reduced volume in the subgenual prefrontal cortex and the hippocampus is a replicated finding in major depressive disorder (Drevets, 1998; Hajek et al., 2008; Rodriguez-Cano et al., 2014) . Less grey matter in the ACC would in theory correspond to fewer synapses and therefore reduced 5-HT 1B receptor binding potential. However, there were no significant differences in grey matter volumes in the ACC or SGPFC ROIs between depressed patients and controls. To our surprise, the hippocampal ROI volume was greater in the patients than in the controls. Reduced hippocampal volumes have been reported in volumetric MRI studies of depression (Arnone et al., 2013; Zhao et al., 2014) . However, in a post-mortem material no differences in hippocampal volumes between depressed patients and controls were found (Bielau et al., 2013) . Moreover, the hippocampus is a plastic brain structure, with a clear association between volume and education level (Janowitz et al., 2014) . There was a trend towards a higher education level in the patients than in the controls in our study (16.4 versus 14.6 years), although this was not significant (p ¼0.169). Importantly, when adjusting BP ND for volume the difference in hippocampal binding between the MDD patients and the controls becomes even more distinct (44% lower BP ND in MDD patients, p¼ 0.001). Furthermore, the PET data were corrected for partial volume effects. Hence, reduced volume cannot explain the low [ 11 C]AZ10419369 binding found in the ACC and associated regions in patients with MDD.
In conclusion, 5-HT 1B receptor binding in the ACC was low in patients with recurrent MDD when compared with controls. The finding corroborates the previously proposed role for ACC in the pathophysiology of recurrent MDD. Further studies are needed to determine if the lower 5-HT 1B receptor binding in the ACC is a vulnerability trait for developing depression or may be related to the depressive state itself.
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